Applied DNA Sciences Inc
APDN4.230USD
-0.340-7.44%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
1.79MCap. mercado
PérdidaP/E TTM
Más Datos de Applied DNA Sciences Inc Compañía
Applied DNA Sciences, Inc. is a biotechnology company. The Company is engaged in developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Company operates through three segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. Therapeutic DNA Production Services segment operations consist of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of messenger RNA (mRNA) therapeutics. MDx Testing Service segment operations consist of performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. DNA Tagging and Security Products and Services segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services.
Información de la empresa
Símbolo de cotizaciónAPDN
Nombre de la empresaApplied DNA Sciences Inc
Fecha de salida a bolsaAug 24, 2001
Director ejecutivoMs. Judith Murrah
Número de empleados46
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 24
Dirección50 Health Sciences Drive
CiudadSTONY BROOK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal11790
Teléfono16312408800
Sitio Webhttps://adnas.com/
Símbolo de cotizaciónAPDN
Fecha de salida a bolsaAug 24, 2001
Director ejecutivoMs. Judith Murrah
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Clay Shorrock, J.D.
Mr. Clay Shorrock, J.D.
President of LRx
President of LRx
4.00
--
Ms. Beth M. Jantzen
Ms. Beth M. Jantzen
Chief Financial Officer
Chief Financial Officer
3.00
--
Ms. Judith Murrah
Ms. Judith Murrah
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.00
--
Mr. Robert B. (Bob) Catell
Mr. Robert B. (Bob) Catell
Independent Director
Independent Director
2.00
--
Dr. Yacov A. Shamash, Ph.D.
Dr. Yacov A. Shamash, Ph.D.
Independent Director
Independent Director
2.00
--
Mr. Joseph D. Ceccoli
Mr. Joseph D. Ceccoli
Independent Director
Independent Director
1.00
--
Ms. Elizabeth M. Schmalz Shaheen
Ms. Elizabeth M. Schmalz Shaheen
Independent Director
Independent Director
--
--
Dr. Sanford R. Simon, Ph.D.
Dr. Sanford R. Simon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Sanjay M. Hurry
Mr. Sanjay M. Hurry
Executive Director - Investor Relations and Corporate Communications
Executive Director - Investor Relations and Corporate Communications
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Clay Shorrock, J.D.
Mr. Clay Shorrock, J.D.
President of LRx
President of LRx
4.00
--
Ms. Beth M. Jantzen
Ms. Beth M. Jantzen
Chief Financial Officer
Chief Financial Officer
3.00
--
Ms. Judith Murrah
Ms. Judith Murrah
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.00
--
Mr. Robert B. (Bob) Catell
Mr. Robert B. (Bob) Catell
Independent Director
Independent Director
2.00
--
Dr. Yacov A. Shamash, Ph.D.
Dr. Yacov A. Shamash, Ph.D.
Independent Director
Independent Director
2.00
--
Mr. Joseph D. Ceccoli
Mr. Joseph D. Ceccoli
Independent Director
Independent Director
1.00
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Product and authentication services - Large scale DNA production
333.66K
33.93%
Product and authentication services - Supply chain
290.23K
29.51%
Clinical laboratory testing services (over-time)
220.55K
22.43%
Research and development services
133.55K
13.58%
Product and authentication services - Asset marking
5.38K
0.55%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product and authentication services - Large scale DNA production
333.66K
33.93%
Product and authentication services - Supply chain
290.23K
29.51%
Clinical laboratory testing services (over-time)
220.55K
22.43%
Research and development services
133.55K
13.58%
Product and authentication services - Asset marking
5.38K
0.55%
Estadísticas de accionistas
Actualizado: sáb., 19 de jul
Actualizado: sáb., 19 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sabby Management, LLC
1.34%
Altium Capital Management LP
1.25%
S.H.N. Financial Investments Ltd
0.97%
Bigger (Michael)
0.96%
Anson Funds Management LP.
0.88%
Other
94.60%
Accionistas
Accionistas
Proporción
Sabby Management, LLC
1.34%
Altium Capital Management LP
1.25%
S.H.N. Financial Investments Ltd
0.97%
Bigger (Michael)
0.96%
Anson Funds Management LP.
0.88%
Other
94.60%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
2.59%
Corporation
1.77%
Individual Investor
0.99%
Hedge Fund
0.89%
Investment Advisor
0.45%
Research Firm
0.03%
Other
93.28%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
62
34.90K
6.72%
-9.01K
2025Q1
84
45.20K
34.86%
+11.50K
2024Q4
79
25.60M
46.39%
+1.44M
2024Q3
74
1.08M
9.78%
+703.30K
2024Q2
73
1.19M
10.83%
+424.27K
2024Q1
67
243.32K
209.10%
+86.27K
2023Q4
64
96.98K
13.46%
-84.74K
2023Q3
66
149.12K
21.28%
-82.31K
2023Q2
68
142.47K
21.43%
-74.27K
2023Q1
68
128.77K
20.06%
-84.88K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Sabby Management, LLC
6.97K
1.34%
+1.29K
+22.64%
Dec 31, 2024
Altium Capital Management LP
6.50K
1.25%
--
--
Apr 03, 2025
S.H.N. Financial Investments Ltd
5.03K
0.97%
--
--
Apr 03, 2025
Bigger (Michael)
5.00K
0.96%
--
--
Apr 03, 2025
Anson Funds Management LP.
4.57K
0.88%
-9.44K
-67.39%
Apr 03, 2025
L1 Capital Global Opportunities Master Fund Ltd.
4.17K
0.8%
--
--
Apr 03, 2025
UBS Financial Services, Inc.
2.31K
0.44%
+2.31K
--
Mar 31, 2025
Grossman (Bruce)
111.00
0.02%
+111.00
--
Feb 02, 2024
Barclays Capital Inc.
80.00
0.02%
+80.00
--
Mar 31, 2025
SBI Securities Co., Ltd.
67.00
0.01%
-90.00
-57.32%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Fecha
Tipo
Relación
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
